Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 1 de 1
1.
ACS Chem Biol ; 12(4): 1020-1027, 2017 04 21.
Article En | MEDLINE | ID: mdl-28195695

The aggregation of neurodegenerative-disease associated proteins can be affected by many factors, including a variety of post-translational modifications. One such modification, O-GlcNAcylation, has been found on some of these aggregation prone proteins, including α-synuclein, the major protein that plays a causative role in synucleinopathies like Parkinson's disease. We previously used synthetic protein chemistry to prepare α-synuclein bearing a homogeneous O-GlcNAc modification at threonine 72 and showed that this modification inhibits protein aggregation. However, the effects of the other eight O-GlcNAcylation sites that have been identified were unknown. Here, we use a similar synthetic strategy to investigate the consequences of this modification at one of these sites, serine 87. We show that O-GlcNAcylation at this site also inhibits α-synuclein aggregation but to a lesser extent than that for the same modification at threonine 72. However, we also find that this modification does not affect the membrane-binding properties of α-synuclein, which differentiates it from phosphorylation at the same site. These results further support the development of therapies that can elevate O-GlcNAcylation of α-synuclein to slow the progression of Parkinson's disease.


Acetylglucosamine/metabolism , Serine/metabolism , alpha-Synuclein/metabolism , Acylation , Cell Membrane/metabolism , Escherichia coli/metabolism , Protein Binding , alpha-Synuclein/chemistry
...